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therapeutic potential of human bone marrow stromal/stem cells (hBMSc) must be developed using well 
defined xenogenic-free conditions. hBMSC were isolated from healthy donors (n = 3) using different 
isolation and expansion methods. Donor I was isolated and expanded by either bone marrow directly 
seeded and cells expanded in 10% AB human serum (AB) +5 ng/ml fibroblast growth factor-2 (FGF2) 
[Direct(AB + FGFlow)] or Ammonium-Chloride-Potassium Lysing Buffer was used before the cells were 
expanded in 10% AB +5 ng/ml FGF-2 [ACK(AB + FGFlow)] or Lymphoprep density gradient medium 
was used before the cells were expanded in 10% AB +5 ng/ml FGF2 [Lympho(AB + FGFlow)] or bone 
marrow directly seeded and cells expanded in 10% pooled platelet lysate plasma (PL) + heparin (2 
I/U/mL) [Direct(PL)]. Groups for donors II and III were: Direct(AB + FGFlow) or 10% AB +10 ng/ml FGF2 
[Direct(AB + FGFhigh)] or Direct(pL). HBMScs were assessed for viability, multi-potency, osteogenic, 
inflammatory response and replicative senescence in vitro after 1 and 3 weeks. Pre-selected culture 
conditions, Direct(AB + FGFhigh) or Direct(pL), were seeded on biphasic calcium phosphate granules 
and subcutaneously implanted in NOD/SCID mice. After 1 and 11 weeks, explants were analysed for 
inflammatory and osteogenic response at gene level and histologically. To identify implanted human 
cells, in situ hybridisation was performed. hBMSc from all conditions showed in vitro multi-lineage 
potency. hBMSCs expanded in PL expressed stemness markers in vitro at significantly higher levels. 
Generally, cells expanded in AB + FGF2 conditions expressed higher osteogenic markers after 1 week 
both in vitro and in vivo. After 11 weeks in vivo, Direct(AB + FGFhigh) formed mature ectopic bone, 
compared to immature mineralised tissues formed by Direct(pL) implants. Mouse responses showed 
a significant upregulation of IL-1α and IL-1β expression in Direct(PL). After 1 week, human cells were 
observed in both groups and after 11 weeks in Direct(AB + FGFhigh) only. to conclude, results showed a 
significant effect of the isolation methods and demonstrated a relatively consistent pattern of efficacy 
from all donors. A tendency of hBMSC expanded in PL to retain a more stem-like phenotype elucidates 
their delayed differentiation and different inflammatory expressions.
Mesenchymal stromal/stem cells are progressively being used in all arenas of tissue engineering and cell-based 
therapies1,2. With regard to bone regeneration, human bone-marrow derived mesenchymal stromal/stem cells 
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(hBMSC) present advantages over other sources of MSC3 and over pluripotent cell types such as induced pluripo-
tent stem cells due to their autologous mode of use, which require less extensive in vitro manipulation or ethical 
clearance, associated with a lower risk4. hBMSC are rare cells, population ranges from 0.001% to 0.01% of the total 
number of nucleated cells present in bone marrow5. Pertaining to this drawback, in vitro cell expansion in mon-
olayers is the most commonly used approach to produce sufficient cell numbers prior to pre-clinical or clinical 
implantations. Despite the increasing number of clinical trials, culturing conditions for hBMSC are still under 
development6. There is substantial evidence that the in vitro expansion phase affects their phenotype, with consid-
erable implications for the development of effective therapies. With hBMSC-based therapies overtaking clinical 
applications in bone regeneration and establishing a new clinical paradigm1,2, the development of production 
methods in accordance with current Good Manufacturing Practices (GMP) is mandatory for a safe and efficient 
regeneration6,7. In compliance with the European Commission regulation 1394/2007, hBMSC are considered 
advanced therapy medicinal products in Europe8.
Clinical translation trials in accordance with GMP require the use of a well-defined culture medium when 
expanding hBMSC to avoid adverse reactions in patients6. Foetal bovine serum (FBS) is derived from the whole 
blood of bovine foetuses and it is a rich source of essential growth factors. These include platelet derived growth 
factor (PDGF), transforming growth factor beta 1 (TGFβ-1), fibroblast growth factor 2 (FGF2), vascular endothe-
lial growth factor (VEGF), insulin-like growth factor (IGF), growth hormones and albumin, making it the opti-
mum and most broadly used supplement for expansion of hBMSC9. However, it comes with safety concerns such 
as zoonotic infections since it contains enogeneic antigens as well as ethical concerns9,10. In addition, the concen-
trations of growth factors in FBS are difficult to control between production batches, and even clinical-grade FBS 
is reported to show variability between its inherent composite of bioactive factors9. To address these issues, alter-
native animal-free strategies are currently being developed for the provision of nutrients and attachment factors 
for culture and expansion of hBMSC. These are generally divided into chemically defined media, and ‘humanised’ 
supplements derived from human blood derivatives. The proposed derivatives include: autologous or allogeneic 
human serum, human platelet derivatives, cord blood serum and human plasma derivatives11.
When comparing hBMSC expanded using human serum to those cultured using FBS, promoted proliferation 
and enhanced gene expressions with genomic stability were portrayed12. Studies mainly using autologous serum 
revealed potential for expansion and osteogenic differentiation of hBMSC; however this potency was shown to be 
age dependant13. Reports on allogeneic serum have been contradictory, and pooling of blood samples seems to 
reduce variability12,14. Use of autologous serum presents with limitations, for instance availability of large quanti-
ties required for clinical applications15. Therefore, alternatives such as pooled human serum from type AB donors 
were introduced.
The physiological role of blood platelets in tissue repair justifies the use of their derivatives in regeneration. 
Human platelet lysate (PL) can be obtained from platelets using different procedures (e.g. thrombin activation, 
freeze/thaw platelet lysis or sonication). It contains an extensive variety of growth factors and cytokines such 
as VEGF, FGF2, epidermal growth factor (EGF), IGF, PDGF and TGF-β1 in higher levels relative to human 
serum16. PL has shown superior efficacy when compared to FBS-propagated cultures. hBMSC were shown to be 
more responsive to chondrogenic and adipogenic stimulation when cultured in PL compared to FBS17. Among 
the advantages of PL is the constancy of its bioactivity even when using expired platelet concentrates18, proving 
comparable proliferation and osteogenic potential when used to culture hBMSC19. PL is highly dependent on the 
preparation method, donor age and blood profile, which makes it difficult to accurately characterise its constitu-
ents; however, pooling can reduce variances20. To avoid the fibrin clots from forming when human PL is added to 
the culture medium, which contains calcium, heparin is usually added to human PL. The levels of heparin have 
shown to variably interfere with the growth rate of cells18. Furthermore, concerns of immunological responses 
and transmission of human infections are also valid as for other human-derived media supplements.
Variation in expansion conditions influences the efficacy and differentiation potential of hBMSCs. This is an 
important consideration when designing tissue engineering and regenerative studies. Most reports comparing the 
human alternatives to FBS have provided contradictory results in their proliferation and differentiation potencies. 
Only few reports have done an inter-comparison among the different human alternatives to highlight the actual 
differences in efficacy21. Increasing cell yield, while maintaining stemness, represents a significant challenge for 
the in vitro expansion of clinical grade hBMSC. Recently, we reported a Phase 1 clinical trial to regenerate den-
toalveolar bone defects where autologous hBMSC were expanded in GMP-grade PL from human pooled platelet 
concentrates as growth factor supplement22. In attempts to improve these protocols and transfer technologies, the 
current study compares different isolation methods of hBMSC and further expansion in different human-derived 
culture media, namely, human AB serum (AB) supplemented with FGF2 or PL. To evaluate the regenerative ther-
apeutic capacity of these cells expanded using different isolation and culture conditions, a systematic assessment 
was carried out both in vitro and in vivo in an ectopic rodent model.
Methods
pooled human platelet lysate preparation. PL plasma was prepared according to published protocols23 
with minor modifications. Briefly, pooled platelets from 4 donors suspended in platelet additive solution was 
spun at 1700 g at room temperature (RT). The resulting pellet was re-suspended in 10 mL Octaplas AB plasma 
(Octapharma AS, Jessheim, Norway) and frozen at −20 °C. This constituted one unit. After thawing, platelets 
from 19 units were pooled and adjusted to a final volume of 4.8 L with Octaplas AB, and subjected to a second 
freeze-thaw-cycle before being centrifuged at 4000 g at 4 °C for 15 min to remove platelet cell wall fragments, and 
subsequently frozen in aliquots. When PL was added to culture medium, 2I/U per mL heparin was added, follow-
ing previously optimised protocols20, to avoid coagulation of the medium through clumping of the fibrinogen in 
the plasma. The platelets used to make PL are all originally donated for use for patients. However, if they are not 
used after 7 days of storage they are deemed unfit for use in patients, and will normally be destroyed, or used for 
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research. We have tested, and found that they may still be used to make PL, as the alternative is that these platelets 
are destroyed. The donors are anonymous to the research laboratory, and the platelet or platelet lysate is not being 
subject to any type of analysis. Ethical approval to use PL in culture conditions was obtained from the Regional 
Committees for Medical and Health Research Ethics in Norway (REK approval no. 2016/1266). All procedures 
were performed in accordance with the relevant guidelines and regulations in the blood bank.
Human bone marrow stromal/stem cells isolation and expansion. HBMSC were isolated from the 
bone marrow of three different healthy donors. A total of 30 to 60 mL of bone marrow was obtained by aspirations 
from the iliac crest under local anaesthesia, after ethical approvals were obtained from the Regional Committees 
for Medical and Health Research Ethics in Norway (REK approval no. S-07043a). All donors gave a written, 
informed consent and all procedures were performed in accordance with the relevant guidelines and regulations. 
The donors were 28, 37 and 37 years of age. The cells were characterised and assessed after isolation using differ-
ent bone marrow processing conditions and expansion culture conditions. Briefly, the whole bone marrow from 
the first donor was divided equally and the different isolation and expansion conditions used are summarised in 
Table 1.
All methods involving humans were performed in accordance with the relevant guidelines and regulations.
The bone marrow from the 2nd and 3rd donors was equally divided and directly seeded without prior process-
ing and expansion conditions are described in Table 2.
The cells were expanded for 2 passages at a laboratory at Norwegian Center for Stem Cell Research in Oslo 
University Hospital before they were transferred to the laboratory at University of Bergen for further in vitro 
differentiation and in vivo osteogenic potential evaluation. The viability of the cells before and after shipment was 
assessed using trypan blue dye.
Multipotent capacity in vitro. Cells were seeded (3–5 × 103 per cm2) in 12-well plates (NUNC, Thermo 
Fisher Scientific, Waltham, USA). Differentiation was induced 2–5 days from seeding (depending on the cells’ 
confluency) using adipogenic medium for 2 weeks and osteogenic media for 3 weeks (all from StemPro, Thermo 
Fischer Scientific). For detection of adipogenic differentiation, cells were stained with Oil Red O stain, while 
mineralisation was detected by Alizarin red staining as described previously24.
Multipotency, inflammatory response, osteogenic and adipogenic differentiation potential and 
replicative senescence in vitro at gene level. Using a Tissue RNA isolation kit (Maxwell, Promega, 
Madison, WI, USA), total RNA was isolated from in vitro osteogenically differentiated hBMSC cultures after 1 
and 3 weeks and undifferentiated controls at 1 week only. Quantity and purity were checked using a Nanodrop 
spectrophotometer (Thermo Fisher Scientific). Total RNA was reverse transcribed according to manufactur-
er’s instructions using the High-capacity complementary DNA Reverse Transcription Kit (Applied Biosystems, 




Bone marrow was directly seeded onto flasks with α-MEM +10% AB serum 
+1% P/S and 5 ng/mL FGF2 (all from R&D)
ACK(AB + FGFlow)
Prepared with Ammonium-Chloride-Potassium (ACK) lysing buffer 
(Gibco) and cells were seeded with α-MEM +10% AB serum +1% P/S and 
5 ng/mL FGF-2
Lympho(AB + FGFlow)
Bone marrow was centrifuged in a density gradient medium Lymphoprep 
(Stemcell Technologies) to isolate mononuclear cells before culturing in 
α-MEM +10% AB serum +1% P/S and 5 ng/mL FGF2 (all from R&D)
Direct(PL) Bone marrow was directly seeded onto flasks with α-MEM +1% P/S (Gibco) +10% PL + heparin (2I/U per mL)
Table 1. Description of the different isolation and expansion conditions for Donor I. Abbreviations: 
α-MEM, alpha minimum essential medium; AB serum, human serum from type AB donors; P/S, penicillin/
streptomycin, FGF2, fibroblast growth factor 2.
DONORS II and III
Abbreviation Description
Direct(AB + FGFlow)
Bone marrow was directly seeded onto flasks with α-MEM +10% AB 
serum +1% P/S and 5 ng/mL FGF2
Direct(AB + FGFhigh)
Bone marrow was directly seeded onto flasks with α-MEM +10% AB 
serum +1% P/S and 10 ng/mL FGF2
Direct(PL) Bone marrow was directly seeded onto flasks with α-MEM +10% AB serum +1% P/S +10% PL + heparin (2I/U per mL)
Table 2. Description of the different isolation and expansion conditions for Donor I and III. Abbreviations: 
α-MEM, alpha minimum essential medium; AB serum, human serum from type AB donors; P/S, penicillin/
streptomycin, FGF2, basic fibroblast growth factor 2.
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using TaqMan gene expression assays (Applied Biosystems). Gene expression assays (Taqman) (Applied 
Biosystems) were used to detect mRNA levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
octamer-binding transcription factor 4 (Oct-4), NANOG and Cluster of Differentiation 90 (CD90) and the 
inflammatory markers interleukin 1 alpha (IL-1α), beta (IL-1β), interleukin 6 (IL-6) and 8 (IL-8) in the undif-
ferentiated controls. mRNA levels of runt-related transcription factor 2 (RUNX2), collagen type 1 alpha 1 (Col 
1α1), alkaline phosphatase (ALP), bone morphogenetic protein-2 (BMP-2), bone sialoprotein (BSP), osteocalcin 
(OC) and GAPDH were detected from osteogenically differentiated cultures at 1 and 3 weeks. mRNA levels 
of adipogenic markers, peroxisome proliferator-activated receptor gamma (PPARG), CCAT/enhancer-binding 
protein alpha (CEBPA) and lipoprotein lipase (LPL) were detected from adipogenically differentiated cultures at 
2 weeks. To evaluate replicative senescence, mRNA level of upregulated genes during cellular aging, Rho GTPase 
activating protein 29 (PARG1/ARHGAP2) and cyclin dependent kinase inhibitor 2 A (CDKN2A) and downreg-
ulated gene pleiotrophin (PTN) were evaluated from osteogenically differentiated cells at 1 and 3 weeks. The data 
were analysed with a comparative CT method and GAPDH served as an endogenous control. Primer details are 
summarised in Supplementary Table 1.
Surface markers evaluation. The results obtained from the in vitro characterisation determined the direct 
seeding isolation method for further evaluation of osteogenic efficacy in vivo. Before seeding on scaffolds, the cells 
from Direct(AB + FGFhigh) or Direct(PL) were stained with mouse anti-human CD44-FITC (Bio SB), CD90-PE 
(eBioscience), HLA-A,B,C-APC (BD Biosciences, USA), HLA-DR-APC (eBioscience), CD105-FITC (Sigma), 
CD14-FITC (Sigma), CD73-PE (BD Biosciences), CD34-FITC (BD Biosciences), CD45-FITC (eBioscience) for 
15 min at RT, before being washed and re-suspended in PBS. Mouse anti-human immunoglobulin isotype anti-
bodies (eBioscience) were used as controls. Acquisition was performed using a BD LSRFortessa cell analyser (BD 
Biosciences) and data were analysed using FlowJo (V10, Flowjo LLC, Ashland, OR, USA).
cell/scaffold constructs’ preparation and subcutaneous implantation. HBMSC from 
Direct(AB + FGFhigh) or Direct(PL) without being osteogenically differentiated were seeded on biphasic calcium 
phosphate (BCP) granules (MBCP; Biomatlante, France) ranging in size from 1–2 mm. Cells (7.5 × 103) per mg 
were seeded on 65 mg of BCP placed in a 96-well plate. Cell-free BCP (BCP alone) served as controls. The plates 
were then shaken in a plate shaker to allow distribution of the cells within the granules and incubated overnight 
at 37 °C and 5% CO2. Two, 1 cm incisions, were made on the back of 8–10 weeks old non-obese diabetic/severe 
combined immunodeficiency (NOD/SCID) mice. The two groups of cell/scaffold constructs or the BCP alone 
groups were randomly distributed and each animal got a total of four subcutaneous implants (n = 8 for each 
group). The mice were sacrificed after 1 and 11 weeks. All animal experiments were approved by the Norwegian 
Animal Research Authority and conducted in strict accordance with the European Convention for the Protection 
of Vertebrates used for Scientific Purposes (FOTS no. 7894).
Osteogenic differentiation potential and inflammatory response in vivo at gene level. Total 
RNA was isolated from in vivo scaffolds 1 week post-implantation and PCR was performed as described previ-
ously for the in vitro samples. Taqman gene expression assays (Applied Biosystems, USA) were used to detect 
mRNA levels of GAPDH, RUNX2, Col1α2, ALP, IL-1α, IL-1β, IL-6 and IL-8 for human and mice. The data were 
analysed with a comparative CT method, with GAPDH as an endogenous control and BCP alone as the reference 
group.
Histological analysis and histomorphometry. After fixation in 4% paraformaldehyde, the harvested in 
vivo scaffold constructs were decalcified in EDTA and cut into half before being processed for paraffin embed-
ding. Sections (3–4 µm) were stained with haematoxylin and eosin (H&E). The histological sections were scanned 
using an Aperio Scanscope Scanner (Aperio Vista, CA, USA) and viewed through Aperio ImageScope software 
program. Qualitative and semi-quantitative histological evaluations were carried out to assess the amount of 
bone formed. The frequency of bone formation was estimated as the number of scaffolds with newly formed bone 
related to the total number of implanted scaffolds.
In-situ hybridisation of the human Alu-sequence. To identify the hBMSC in the cell/scaffold con-
structs harvested after the in vivo implantation, in situ hybridisation using the human-specific repetitive Alu 
sequence was performed as previously described25. Briefly, paraffin sections were treated for heat induced epitope 
retrieval for 20 h at 60 °C in citrate buffer 10 mM (pH 6) plus Tween 20 0.05% followed by 0.25% acetic acid 
in 0.1 M triethanolamine (pH 8) for 20 minutes at RT. Prehybridisation was performed for 3 hours at 56 °C in 
a hybridisation buffer containing 4 × Saline-Sodium Citrate buffer (SSC) (Sigma-Aldrich), 50% deionised for-
mamide, 1 × Denhardt’s solution, 5% dextran sulfate, 100 μg/ml salmon sperm DNA and molecular-grade water. 
Hybridisation buffer was refreshed with the addition of 70 nM custom DIG-labelled human locked nucleic acid 
Alu probe 5DigN/5′-TCTCGATCTCCTGACCTCATGA-3′/3DigN (Exiqon, Vedbaek, Denmark) and then tar-
get DNA and the probe were denatured for 1 h  at 70 °C. Hybridisation was carried out overnight at 56 °C. The 
hybridised probe was detected by immunohistochemistry using biotin-SP conjugated IgG fraction monoclonal 
mouse anti-digoxin (Jackson Immunoresearch, West Grove, Pennsylvania, USA) diluted 1/400 in Tris-buffered 
saline with Tween, 2% bovine serum albumin for 1 h at RT. Stretoperoxidase was added (1/400 in Tris-buffered 
saline with Tween) for 35 min at RT. All bound reactions were visualised with 3,3′ diaminobenzidine substrate 
(Dako, Les Ulis, Ile-de-France, France). Sections were counterstained with Gill-2 hematoxylin (Thermo Shandon 
Ltd, Runcorn, UK).
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Statistical analyses. All data are presented as the mean values + standard error of the mean. Average values 
were analysed using SPSS Statistics 25.0 (IBM, Armonk, NY, USA). Data were tested for variance homogeneity 
and normal distribution and One-way ANOVA were followed by a multiple- comparison LSD test. Differences 
between the means were considered statistically significant when p < 0.05.
ethics approval. Bone marrow samples were collected after ethical approvals were obtained from the 
Regional Committees for Medical and Health Research Ethics in Norway (REK Approval No. S-07043a). The 
samples were collected following an informed consent of the patients. All animal experiments were approved by 
the Norwegian Animal Research Authority and conducted in strict accordance with the European Convention 
for the Protection of Vertebrates used for Scientific Purposes (FOTS No. 7894).
Results
Cells’ viability was maintained after 24 h shipment. The expanded hBMSC were transported within 
24 hours from Oslo (Norway) to Bergen (Norway) at RT via DHL Express overnight courier. The majority of the 
cells cultured in different conditions expressed viability above 90%. Their viability on arrival at Bergen is sum-
marised in Table 3.
hBMSC preserved variable degrees of stemness when cultured under different conditions. 
Undifferentiated hBMSC expressed significantly higher levels of CD90 mRNA when they were isolated directly 
from bone marrow and expanded in PL for all donors. The transcription factors regulating pluripotency, NANOG 
and Oct-4, were significantly upregulated in the cells that were isolated directly from bone marrow and expanded 
in PL for all donors, followed by Lympho(AB + FGFlow) in donor I and Direct(AB + FGFhigh) in donor II and 
III (Fig. 1a). Cells from all donors expanded under all different conditions tested showed multipotency when 
induced. The osteogenic differentiation was confirmed by presence of a mineralised matrix when stained for 
Alizarin red. Cells expanded with AB + FGFhigh were observed to have the strongest Alizarin red stain, as assessed 
macroscopically (Fig. 1b). The adipogenic lineage was defined by the formation of lipid vacuoles stained by Oil 
red (Fig. 1c).
Different isolation and culture conditions influenced the inflammatory responses in vitro. The 
mRNA of pro- and anti-inflammatory markers displayed variable expression among different groups. IL-1α, 
the pro-inflammatory marker showed the highest expression in Direct(AB + FGFlow) for all donors (Fig. 2). The 
lowest expression in donor I was detected in cells from Lympho(AB + FGFlow) (Fig. 2a). However, when only the 
Direct seeding method was compared for donor II and III, the lowest expression was seen in cells from Direct(PL) 
(Fig. 2b). The lowest expression for IL-1β was presented by cells from Direct(PL) for all donors.
IL-6 showed the highest significant expression in cells from Direct(PL); however for donor I and III the cells 
from Direct(AB + FGFlow) showed the highest expression, followed by cells from Direct(PL). The mRNA expres-
sion of IL-8 showed more consistency among the donors where cells expanded under AB + FGF portrayed the 
highest expressions.
Different isolation and culture conditions influenced the osteogenic differentiation potential 
of the cells in vitro. The mRNA expression of most of the osteogenic markers showed generally comparable 
trends among all isolation and cell culture conditions tested here (Fig. 3). The early transcription factor RUNX2 
continued to be upregulated significantly from 1 to 3 weeks in all groups. After 1 week, cells isolated by direct 
method and cultured in AB + FGF showed the highest expression of RUNX2 for all donors. Early osteogenic 
marker, Col1α1, displayed a significant upregulation from 1 to 3 weeks in all groups except Direct(AB + FGFhigh) 
for donor II which showed an inversed trend. Generally, cells grown in AB serum, regardless of the isolation 
method showed higher expression at both time points compared to cells in PL.
ALP mRNA expression was significantly downregulated for all groups after 3 weeks except for Direct(PL), 
where it was upregulated in cells from donors II and III. The highest expression at both time points was in cells 
from Lympho(AB + FGFlow) for donor I followed by cells from Direct(PL). For donor II and III, cells from 




Cell viability 24 h 
later
Donor I
Direct(AB + FGFlow) 97% 85%
ACK(AB + FGFlow) 98% 91%
Lympho(AB + FGFlow) 98% 91%
Direct(PL) 92% 84%
Donor II
Direct(AB + FGFlow) 96% 94%
Direct(AB + FGFhigh) 96% 93%
Direct(PL) 97% 92%
Donor III
Direct(AB + FGFlow) 98% 96%
Direct(AB + FGFhigh) 98% 95%
Direct(PL) 98% 92%
Table 3. Viability of cells after shipment.
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The mRNA expression of BMP-2 showed a consistent significant upregulation after 3 weeks for donor I and 
donor III in all culture condition groups. However, a downregulation was observed after 3 weeks in donor II 
for most groups. The highest BMP-2 mRNA expression at both time points were seen from cells expanded in 
AB + FGF either by the ACK or Direct seeding method.
Figure 1. Multipotency characterisation in vitro. (a) Relative mRNA expression of MSC marker, CD90 and 
transcription factors regulating pluripotency, NANOG and Oct-4 after 1 week of non-induced culture after 
transport. Expression is presented relative to the Direct(AB + FGFlow) group (p < 0.05). (b) Alizarin stain 
showing cells from all culture conditions and from all donors differentiated consistently into the osteogenic 
lineage when induced. (c) Oil red O stain confirming lipid vacuoles when adipogenic lineage was induced.
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BSP mRNA presented comparable trends of expression among all groups for all donors. There was a signifi-
cant upregulation after 3 weeks in all groups, with the highest expression from cells grown in AB + FGF in general 
and specifically ACK(AB + FGFlow) for donor I. Osteocalcin, a late osteogenic marker, was significantly upregu-
lated after 3 weeks along all culture condition groups for all donors. The highest osteocalcin mRNA expressions at 
both time points were seen from cells isolated and expanded in ACK(AB + FGFlow) for donor I and similary cells 
grown in AB + FGF from donor II and III. Direct(PL) cells showed the lowest expression of BSP and osteocalcin 
at both time points for all donors.
Different isolation and culture conditions influenced the adipogenic differentiation potential of 
the cells in vitro. The mRNA expression of the adipogenic markers was evaluated at 2 weeks and it showed 
largely comparable trends among all isolation and cell culture conditions tested, proving the adipogenic differen-
tiation and thus multipotency of the cultured hBMSC (Fig. 4).
The highest expressions in all adipogenic markers (PPARG. CEBPA and LPL) were from Lympho(AB + FGFlow) 
cells from donor I and the lowest expressions from Direct(PL) cells. Cells grown in AB + FGF in general from 
donor III expressed higher levels compared to Direct(PL) in all markers. Donor II showed variable expressions 
among the three markers between the groups.
Different isolation and culture conditions influenced the replicative senescence of the cells. 
The mRNA expression of a combination of the commonly upregulated and downregulated genes associated with 
cellular aging were evaluated after 1 and 3 weeks of osteogenically differentiated cells cultured in the different 
conditions. Significant differences were observed between the different expansion conditions and between time 
points (Fig. 5). The mRNA expression of PTN at 1 week was comparable between all groups, however after 3 
weeks there was an upregulation in all groups and significantly higher upregulation was observed in the AB + FGF 
groups in general in donor II and III. These results might elucidate the survival of Direct(AB + FGFhigh) in vivo 
up to 11 weeks compared to cells cultured in Direct(PL). PARG1 was significantly expressed lower in Direct(PL) 
in donor II and III in week 1 and CDKNA2 showed similarly the lowest expression significantly in Direct(PL) in 
all donors at week 1. After 3 weeks, Direct(PL) showed the highest expression of PARG1 in donor II and III and 
AB + FGF groups generally showed higher expressions in CDKNA2 (Fig. 5).
Different culture conditions influenced the inflammatory and host response potential of the 
cells in vivo. Before in vivo implantation, cells from Direct(AB + FGFhigh) and Direct(PL) showed comparable 
expressions of all the tested surface cell markers (data not shown) except for HLA-DR + where the percentage and 
intensity reduced considerably in cells from Direct(PL) for both donors II and III (Fig. 6a). Implanted hBMSC 
did not express any human inflammatory genes in vivo (data not shown). Mouse inflammatory responses showed 
an upregulation of IL-1α and IL-1β expression in Direct(PL) (Fig. 6b). The marker IL-6 was upregulated in cells 
from Direct(AB + FGFhigh) and there was no expression for IL-8.
Figure 2. mRNA expressions of inflammatory markers in vitro 1 week post transport. Different groups 
evaluated from (a) donor I and (b) donor II/III. Y axes represent relative mRNA expressions for IL-1α, IL-1β, 
IL-6 and IL-8. Expression is presented relative to the Direct (AB + FGFlow) group, (p < 0.05).
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Histologically, inflammatory cells (neutrophils, plasma cells and lymphocytes) infiltrated all implants in the 
first week (Fig. 6c red arrows). More inflammatory cells were detected in Direct(AB + FGFhigh) and Direct(PL). 
Fibroblast-like cells were visible within a dense connective tissue close to the granules in Direct(AB + FGFhigh) 
and Direct(PL), compared to the interlaced areas of loose connective tissue observed in BCP alone. Thick and 
organised layers of collagen bordering the granules with cells from Direct(AB + FGFhigh) group (Fig. 6c black 
arrows)were observed as compared to cells from BCP alone and Direct(PL) group. Peripheral resorption/
Figure 3. mRNA expressions of osteogenic markers in vitro after 1 and 3 weeks post transport. Y axes represent 
relative mRNA expressions for RUNX2, Col1α1, ALP, BMP-2, BSP and OC. Expression is presented relative to 
the Direct(AB + FGFlow) group at 1 week, (p < 0.05).
9Scientific RepoRtS |         (2019) 9:16031  | https://doi.org/10.1038/s41598-019-52442-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
degradation of the granules was greater in Direct(AB + FGFhigh) compared to the control and to Direct(PL) and 
cells could be identified within the pores of the granules in Direct(AB + FGFhigh) (Fig. 6c blue arrows).
After 11 weeks in vivo multi-nucleated giant cells were seen in close contact to the peripheries of the granules 
in all implanted groups mostly in the BCP alone and Direct(PL) groups (Fig. 6d black arrows). Integration of 
the granules with the surrounding tissues appeared to be less obvious, with a decrease in granules’ surface area, 
indicative of accelerated resorption than at 1 week. The granules in Direct(AB + FGFhigh) continued to degrade 
faster, thus the less visible multi-nucleated giant cells. Granules were situated between areas of dense and disperse 
connective tissue, with the connective tissue closer to the granules being more dense in the Direct(AB + FGFhigh) 
and Direct(PL) groups compared to the control. Cellular connective tissue with scattered fibroblast-like cells was 
more prominent in Direct(PL) (Fig. 6d red arrows).
In vivo osteogenic potential showed variability with different culture conditions. After 1 week 
there were no expressions for mice osteogenic genes; however the human genes from hBMSC were expressed after 
implantation. All osteogenic markers evaluated, RUNX2, COL1α2, ALP showed a consistent significant upregu-
lation in the Direct(AB + FGFhigh) group compared to the control and Direct(PL).
Histological sections examined for mineralisation showed that after 11 weeks in vivo, the frequency, mat-
uration and quantity of ectopically formed bone were different among the different groups. Cells from 
Direct(AB + FGFhigh) formed mature mineralised ectopic bone in 83% of the animals, compared to immature 
mineralised tissues formed in only 17% of the animals implanted with Direct(PL). BCP alone showed no signs 
of mineralisation, however there were areas of dense collagen seen around the granules. Osteocytes in lacu-
nae were found within the bone like structures in Direct(AB + FGFhigh) (Fig. 7b black arrows). Also, cuboidal 
osteoblast-like cells were seen surrounding the peripheries of the granules and bordering the newly formed bone.
Figure 4. mRNA expressions of adipogenic markers in vitro after 2 weeks post transport. Y axes 
represent relative mRNA expressions for PPARG, CEBPA and LPL. Expression is presented relative to the 
Direct(AB + FGFlow) group, (p < 0.05).
1 0Scientific RepoRtS |         (2019) 9:16031  | https://doi.org/10.1038/s41598-019-52442-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
The Direct(PL) group histologically contained more areas of dense collagen and the de novo-formed bone 
appeared to have a higher ratio of mineralised immature ‘bone-like’ regions (Fig. 7b red arrows).
identifying implanted human BMSc in vivo. In situ hybridisation using the human-specific repeti-
tive Alu sequence demonstrated that in vivo explants were populated primarily by host connective tissue cells 
(fibroblasts) depicted by the purple nuclei and purple fibers. Human cells were identified with brown nuclei 
and were observed after week 1 in both Direct(AB + FGFhigh) and Direct(PL) groups (Fig. 8a black arrows). At 
week 1, human cells in Direct(PL) were seen to infiltrate a dense connective tissue that is organised and wrapped 
around the periphery of intact BCP granules. On the contrary, the human cells in Direct(AB + FGFhigh) were 
observed to populate a looser connective tissue (less organised) that is surrounding BCP granules that are less 
integrated. A similar picture of loose connective tissue with less human cell population was observed surround-
ing the less integrated BCP granules in Direct(PL) explants. Morphologically, no differences were observed 
between the human cells infiltrating in both groups. After 11 weeks human cells were detected in the explants 
from Direct(AB + FGFhigh) only (Fig. 8b black arrows). The human cells were found embedded in osteocyte lacu-
nae within the mineralised bone formed ectopically with no cells found in the surrounding connective tissue. No 
inflammatory cells were identified infiltrating the connective tissue or bone which is populated with human cells.
Discussion
In this study, we compared different isolation conditions of MSC from human bone marrow and expansion in 
different ‘humanised’ media, specifically, human AB serum (AB) supplemented with FGF2 or PL. Several studies 
have confirmed that human derivatives can substitute for FBS in expansion of MSC26,27 and therefore this com-
parison was not the objective of the current study. Clinical applications of MSC require a cell number that cannot 
be provided by simple bone marrow aspiration, therefore, an ex vivo expansion step is inevitable. However, their 
clinical applications may be limited by the ability to expand their cell numbers in vitro while maintaining their 
differential potentials and stem cell properties/‘stemness’.
In a GMP system, cells are produced under the highest quality requiring product reproducibility6,7. Cell sur-
vival and quality assurance are essential aspects to be considered in addition to the therapeutic potency. Taking 
this into consideration, the viability of our cells after shipment was considered comparable to that before ship-
ment, hence successful. However, in some occasions, the GMP facilities are not in close proximity to the clinical 
Figure 5. mRNA expressions of replicative senescence genes after 1 and 3 weeks in osteogenic culture. Y axes 
represent relative mRNA expressions for PARG1, CDKN2A and PTN. Expression is presented relative to the 
Direct(AB + FGFlow) group, (p < 0.05).
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centre where the cell therapy is taking place. The ability to preserve MSC phenotype and function in a sterile 
condition until the confirmation of an absence of bacterial contamination is important for quality control prior to 
clinical transplantation28. Dimethylsulfoxide (DMSO) and FBS are commonly used as cryoprotectants. However, 
Figure 6. In vivo inflammatory and host responses. (a) Representative histograms of flow cytometry analysis 
showing HLA-DR expression on hBMSC pre-implantation; monoclonal antibody control (yellow) and the 
stained cells (red). (b) Mouse relative mRNA expressions 1 week post-implanting of the BCP and cell constructs 
in vivo. Y axes represent mRNA expressions for IL-1α, IL-1β, IL-6 (p < 0.05). (c) Histological micrographs 
after 1 week of the different groups implanted. Magnification 400× showing the different inflammatory cells 
recruited. L - lymphocytes, N - neutrophils, P - plasma cells. (d) Histological micrographs after 11 weeks 
showing recruited foreign body giant cells (black arrows) and a cellular connective tissue with scattered 
fibroblast-like cells in Direct(PL) (red arrows). Scale 100 µm.
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the use of DMSO can result in toxicity while animal proteins present in serum-supplemented culture media, can 
induce immune responses after transplantation. Cryopreserving the MSC in xeno-free can promote cell therapy 
‘off the shelf ’, but the cryostorage protocols need to evaluated thoroughly to test the resiliency of the cells. This 
has been effectively presented with autologous plasma used as a cryoprotectant in combination with DMSO, 
where it preserved human MSC’s therapeutic efficacy after rapid thawing and implantation28. However, it has 
been reported that the cells’ behaviour can be affected by different cryoprotectants29. Platelet lysate as a cryo-
protectant revealed comparable efficacy compared to FBS30, however how the different types of human-derived 
cryoprotectants preserve MSC need to be compared in a bone regeneration context. In our results (Table 3), cells 
expanded in Direct(PL) showed the highest viability in Donor II and III, although this higher viability, compared 
to the other groups, was not conserved after 24 h of shipment in room temperature. Moreover, we have previ-
ously shown that expansion medium supplemented with PL allowed bone marrow MSC to continue proliferating 
steadily for more than 120 days31. Therefore, due to the presence of high amounts of growth factors and cytokines, 
particularly PDGF in PL16, which has an anti-apoptotic effect on progenitor cells32, we could conjecture that PL 
Figure 7. mRNA expression of human osteogenic markers in vivo and de novo bone formation. (a) Relative 
mRNA expressions after 1 week in vivo. Y axes represent relative mRNA expressions for RUNX2, COL1α2 and 
ALP relative to endogenous reference GAPDH. Expression is presented relative to BCP alone (p < 0.05). (b) 
Histological micrographs after 11 weeks showing mature mineralised ectopic bone (blue arrows), osteocyte 
lacunae in Direct(AB + FGFhigh) explants (black arrows) and immature bone-like regions in Direct(PL) (red 
arrows). Scale 100 µm. (c) Histomorphometrical analyses of the frequency and quantity of bone formed in the 
different implant groups after 1 and 11 weeks.
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is a cryoprotectant that could preserve the high viability and proliferative capacity expressed during thawing and 
expansion. However, success of survival after engraftment is not necessarily a similar reflection.
Concerns that the monolayer expansion phase of MSC results in loss of multipotency, the ability to self-renew, 
and promotes a tendency toward osteogenesis have been previously reported33. In our study, hMBCs before differ-
entiation were analysed for presence of pluripotency markers Oct-4 and NANOG, which are reported to function 
in coherence as key transcription factors for the pluripotent and self-renewing phenotypes of undifferentiated 
embryonic stem cells34,35. However, their role in the self-renewal and undifferentiation of MSC is controversial 
with postulated mechanisms behind their role in maintaining MSC in an undifferentiated state36. Interestingly, 
the MSC expanded in PL were highly positive for Oct-4 and NANOG mRNA, therefore, PL maintained primitive 
MSC during expansion, compared with that in AB serum. Similarly, a study using PL showed that MSC preserve 
their multipotency with elevated expressions of Oct-4 and NANOG compared to when FBS is used to expand 
MSC37. This can be considered advantageous since this will likely affect the functional outcomes following in 
vivo transplantation. Compared with other human supplements, PL was reported to be the human-derived sup-
plement of choice for expanding hBMSC in recent clinical trials22. Additionally, CD90, a marker expressed by 
bone marrow subpopulations of CFU-F38, was upregulated in Direct(PL) for all donors and least expressed by 
Direct(AB + FGFlow) for all donors, which highlights the role played by PL in preserving the MSC multipotency. 
Nevertheless, many studies have shown that expansion of MSC in different types of media can lead to increased 
heterogeneity and enrichment of certain subpopulations, which can affect cellular genotypes and phenotypes39. 
Reports have shown that addition of PL to the medium produces MSC with a reduced adipogenic differentiation 
potential, whereas other studies have shown that it favours osteogenesis and chondrogenesis40–42. These conflict-
ing outcomes may be attributed to inconsistency in preparation procedures as well as the effects of PL donors of 
different ages43.
Figure 8. Human cell identification by in situ hybridisation of the human-specific repetitive Alu sequence. 
(a) Micrographs showing human cells 1 week post-implantation populated with host cells (purple nuclei) and 
human cells (brown nuclei) surrounding BCP granules in both Direct(AB + FGFhigh) and Direct(PL) (black 
arrows). Human cells populating dense connective tissue in Direct(PL) compared to a loose connective tissue in 
Direct(AB + FGFhigh). (b) Human cells identified by the brown nuclei (black arrows) in osteocyte lacunae (black 
arrows) within the mineralised bone formed in Direct(AB + FGFhigh) after 11 weeks post implantation. Scale 
100 µm.
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Our results also showed variability in the expression of the stemness markers among the groups where hBMSC 
were expanded in AB + FGF but using different isolation methods. This highlights the additional role played by 
isolation methods in the cell phenotype/genotype. MSC are isolated from bone marrow using different methods 
by different laboratories; these include directly plating the whole bone marrow, density centrifugation, red blood 
cell lysis and magnetic/fluorescence activated cell sorting. In our study, one of the methods used to isolate MSC 
was processing by density centrifugation, using Lymphoprep density media. In donor I, Lympho(AB + FGFlow) 
portrayed the second highest expression for stemness markers after Direct(PL). Density centrifugation separates 
the mononuclear cell fraction from the other cellular or non-cellular constituents in bone marrow aspirate (e.g. 
red blood cells). The resulting mononuclear cells include a mixed population, such as T cells, B cells monocytes, 
hematopoietic stromal cells and MSC. The density centrifugation process itself reduces the total yield of mon-
onuclear cells from bone marrow44, but may increase the colony forming unit fibroblasts (CFU-F) efficiency 
compared to direct plating/seeding and ACK lysis methods45. This can explain their higher expressed stemness. 
Inter-donor variations cannot be avoided, however, to rule out variations that have been demonstrated when 
comparing the phenotype of MSC population derived from two serial bone marrow aspirates from the same 
person46, the same bone marrow sample was divided and processed differently in this study.
In our AB serum, it was supplemented with FGF2, and purified growth factors, such as FGF2, are added to 
culture conditions even in the presence of FBS or blood-derived supplements to enhance proliferation and over-
all behaviour47. FGF2 is a known mitogen of MSC, also functioning to maintain multipotency and to promote 
subsequent differentiation in vitro47,48. However, their effects can greatly vary depending on their concentrations 
and interactions, as portrayed by our results. The concentration of FGF-2 was doubled, but that increase was not 
reflected directly on the expression of osteogenic genes for example. Concentrations, not standard, up to 10 ng/ml 
of FGF2 are reported in the literature, causing difficulties when attempting to compare studies.
In vitro inflammatory gene expressions were evaluated in undifferentiated hBMSC to evaluate the role played 
by the isolation and expansion conditions solely. The pro-inflammatory marker IL-1α was least expressed in 
Lympho(AB + FGFlow). This method compared to others involves the selection of the bone marrow mononuclear 
cells and it is in line with a previous report where directly seeding complete bone marrow or using methods 
not involving selecting mononuclear cells preserved the immunomodulatory capacity of MSC49. IL-6 and IL-8 
are inflammatory cytokines that play important roles in osteogenic differentiation for bone regeneration and 
remodelling50,51. Our results showed the highest expression of IL-6 from Direct(PL) in donor I and the second 
highest in donor II and III. The secretion of IL-6 was shown to be increased by MSCs cultured with PL compared 
with FBS52 and IL-6 has been reported to maintain MSC stemness53. Considering that Direct(PL) cells showed 
a relatively late osteogenic differentiation, this explains the reverse expressions of IL-8, since in bone regener-
ation this marker is involved with osteoclast function which is in late stages of remodelling50. MSC have the 
ability to express HLA-II when exposed to inflammatory stimulants54 and these stimulations trigger their immu-
nosuppressive function55. HLA-II antigens are recognised by CD4 + T lymphocytes, and MSC avoid immune 
rejection by immunomodulation of the local environment56. HLA-DR is an MHC class II cell surface receptor, 
and a stronger expression of HLA-DR compromises the immune privilege of MSC57. Direct(PL) cells showed 
a lower expression of HLA-DR compared to Direct(AB + FGFhigh), which correlates with the more ‘stemness’ 
phenotype expressed from Direct(PL) cells and their higher expression of anti-inflammatory marker IL-6 in vitro 
and reduced pro-inflammatory markers (IL1α and β). It has been reported that the HLA-II expression in MSC 
displays an inversely proportionate relation with the stemness of the cells58.
Nevertheless, the impact of HLA-DR expression on MSC potency and function remains controversial due to 
its dynamic expression from MSC in culture with time56. Different culture conditions (human serum versus plate-
let lysate) were not found to affect the HLA-DR expression from BMSC56, however addition of FGF was reported 
to express higher HLA-DR in BMSC compared to when cells were cultured in platelet lysate59, in line with our 
results. The expression of HLA-DR has been suggestive of differentiation commitment56, which can explain the 
osteogenic potential of cells from AB + FGF in vitro and in vivo.
In vivo, when the hBMSC were implanted, no human inflammatory markers were detected at mRNA level, 
however the implanted cells posed varying inflammatory reactions from the host cells between groups.
Our in vitro osteogenic differentiation results showed mostly elevated expressions of osteogenic markers 
when cells were generally expanded in AB + FGF2. It has been reported previously that MSC cultured in FBS 
in combination with FGF-2 showed a superior growth compared to PL49. However, a closer look into when the 
different isolation methods were compared in donor I, a significant difference was portrayed even when the cells 
were expanded in the same media (AB + FGF2). The bone markers BMP-2, BSP and osteocalcin showed signif-
icantly higher expressions after 3 weeks in the ACK(AB + FGFlow). This can be attributed as well to the fact that 
other isolation methods, such as density centrifugation increase the sub-population of naive MSC more prone to 
self-renewal than differentiation45.
MSC expanded in PL showed relatively higher expressions in the early bone markers, such as RUNX2 and 
ALP. This compliments the high stemness markers that were expressed which propose the late differentiation of 
the cells in this condition. A previous study reported that addition of FGF-2 in the culture medium resulted in 
reduction in expression of ALP60, which could be a postulation for our higher ALP expressions from Direct(PL) 
in donor II and III. Besides the naive MSC state in the Direct(PL), another factor for the lesser osteogenic poten-
tial could be the addition of heparin in the medium to prevent gel formation. It was shown that a relatively high 
concentration of heparin in culture media supplemented with human PL compromises proliferation as well as 
adipogenic and osteogenic differentiation of MSC61.
Characterising hBMSC performance and potency as a therapeutic entity requires additional tests for in vivo 
differentiation potential. Based on the in vitro results, the direct seeding method was chosen to go further. This 
helps to reduce confounding factors and establish methods easy to standardise with least manipulation for the 
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bone marrow aspirates. As previously reported, MSC expanded in FBS are able to undergo bone formation 
when implanted on BCP scaffolds62, however it is important to define that this characteristic and quintessential 
multipotent MSC phenotype are not lost with the optimised humanised culture conditions proposed in this study.
In vivo, hBMSC expressed the osteogenic genes (RUNX2, COL1α2 and ALP) when expanded in 
Direct(AB + FGFhigh) and showed a higher frequency of bone formation too, which reflects cell survival and 
differentiation, indicating a direct contribution of the implanted hBMSC in bone formation. Interestingly, the de 
novo bone in Direct(PL) seemed to have immature regions with more disorganised collagen, suggestive of woven 
bone morphology and indicating tissue-formation processes were still continuing after 11 weeks of implanta-
tion. This can be reflected on the higher self-renewing potential of the cells in this group that was depicted in 
vitro. When observed closely, the collagen of the new bone in the Direct(AB + FGFhigh) group appeared much 
more organised with residing osteocytes within lacunae, suggestive of lamellar structure. Several studies suggest 
a direct contribution of MSC to regenerate bone as they differentiate into osteoblastic lineage when implanted 
locally, and contrary studies postulate that the implanted MSC exert a paracrine effect on host cells thus home 
circulating hematopoietic progenitors63 and endogenous osteogenic progenitor cells64. The in situ hybridisation 
results suggest the cells from the different groups might have contributed differently when forming bone. In 
Direct(AB + FGFhigh) human cells were still identified after 11 weeks, located in the lacunae of mature mineralised 
bone, which was not the case for Direct(PL). It could be that the less differentiated cells from Direct(PL) released 
cytokines and growth factors to recruit endogenous progenitor cells. Although no human cytokines were detected 
from the explants, however the mouse pro-inflammatory markers detected were highly expressed in this group. 
Therefore, the host inflammatory environment induces the recruitment and the homing of MSC65. IGF-1 and 
PDGF that are reported to play a role in homing MSC66 are major constituents of PL16.
Replicative senescence is reflected by significant morphological changes; cellular enlargement, debris and 
vacuoles intracellulary leading to a cease of proliferation67. The cells in our study were expanded for only 2 pas-
sages before they were used in the in vitro and in vivo experiments. No senescent/related morphological changes 
or phenotypical changes were identified when the cells were routinely observed macroscopically. However, 
previous reports have shown that replicative senescence of MSC is a continuous process starting from the 
first passage67, and this process includes, in addition to alterations in phenotype and differentiation potential, 
senescence-associated gene expression changes. Therefore, to reflect the heterogeneity in the cellular aging pro-
cess, global gene expression patterns have been evaluated and still constantly identified. PTN demonstrated to 
play important roles in survival and self-renewal of human embryonic stem cells and retention of bone marrow 
hematopoietic stem cells. Its down-regulation was shown to be associated with decline of proliferation capacity 
of senescent MSC68. The mRNA expression of PTN after 3 weeks with a significantly higher upregulation in the 
AB + FGF groups in general in donor II and III could elucidate the survival of Direct(AB + FGFhigh) in vivo up 
to 11 weeks compared to cells cultured in Direct(PL). The trend was reflected in the other markers, PARG1 and 
CDKNA2, cell cycle inhibitors that were downregulated in Direct(PL) in most donors in week 1. Replicative 
senescence-associated gene expression changes in hBMSCs isolated in different methods and expanded under 
xenogenic and xeno-free culture conditions demonstrated high similarity68. From our results, an effect of culture 
conditions on the senescence of the cultured hBMSC could be detected and an explanation for the in vivo cell 
survival and in vivo performance of the different groups can be postulated. However, several factors can be con-
sidered that influence the variation on gene expressions in vitro, such as donor age and cell density.
In addition to the isolation methods, the differing behaviours of MSC can be ascribed to the different cytokine 
contents of AB serum and PL. Also this might mean that 10% supplement of each is not a standard comparison 
as it may seem. It has been documented, for example, that age-related differences in human serum and PL com-
position occur and have a direct effect on MSC performance43; however, our results are related to commercially 
available allogeneic serum pooled from many hundred donors and PL pooled from 76 donors. A combination 
of human serum and PL to supplement culture medium showed an improved proliferation of MSC compared to 
when expanded in only human serum21.
In our results, Direct(AB + FGFhigh) cells expressed superior osteogenic potential in vivo, and these cells were 
identified until 11 weeks in vivo. This indicates that the poor survival of transplanted cells is a limitation for clin-
ical regeneration that depend on long-term engraftment. A better understanding of how the cytokines present in 
inflammatory environments in vivo moderate MSC could be useful to develop more effective priming strategies 
to enhance MSC survival and subsequent therapeutic efficacy.
Coupling GMP xeno-free MSC production with the manufacturing of primed MSC can be considered as 
complementary strategies to enhance cell survival and therapeutic efficacy. Potential mechanisms of MSC primed 
therapeutics include gene editing69 to engineer MSC and thus promoting tissue regeneration through cell differ-
entiation70. Moreover, via the delivery of bioactive factors through different secretory modes including ex vivo cell 
engineering71 or the production of induced MSC from induced pluripotent stem cells and preserve immunomod-
ulatory characteristics in addition to enhanced cell survival and proliferation57.
conclusions
To fully recognise and exploit the therapeutic potential of MSC, an inclusive evaluation of their stemness, lineage, 
cell surface markers and transcription factors, in line with their isolation and expansion was required. In our 
work, we evaluated the effects of isolation methods and ‘humanised’ culture conditions on the potency of bone 
marrow derived MSC. Taken together, our results showed a significant effect of the isolation method and demon-
strated a relatively consistent pattern of efficacy from 3 donors, and portrayed a tendency of hBMSC expanded in 
PL to retain a more stem-like phenotype which elucidates their delayed differentiation and different inflammatory 
expressions.
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